Great Point Partners’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Great Point Partners’s Portfolio SRRA Stock Details SRRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-12,271	Closed	-$834K	–	44
2018 Q3	$834K	Sell	12,271 -44,752	-78%	-$4.06M	0.13%	28
2018 Q2	$6.75M	Sell	57,023 -20,755	-27%	-$2.08M	0.94%	30
2018 Q1	$6.44M	Buy	+77,778	New	+$8.82M	0.96%	25

Other funds holding SRRA

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Great Point Partners's SRRA Position: Q4 2018 in Review

Great Point Partners sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q4 2018, closing a stake of 12,271 shares — an estimated $834K sold.

Great Point Partners first reported a position in SRRA in Q1 2018 and held it in 3 quarters. The position peaked at $6.75M in Q2 2018. 61 funds tracked by Wall St. Rank hold SRRA as of Q4 2018.

Great Point Partners reported no remaining Sierra Oncology, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Great Point Partners sold 12,271 Sierra Oncology, Inc. Common Stock shares in Q4 2018, an estimated $834K.
Great Point Partners first reported a position in Sierra Oncology, Inc. Common Stock in Q1 2018 and held it in 3 quarters.
Great Point Partners's Sierra Oncology, Inc. Common Stock position peaked at $6.75M in Q2 2018.
61 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q4 2018.

Based on Great Point Partners's 13F filing for Q4 2018, filed 15 Feb 2019.